A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: NUT Midline Carcinoma (NMC)|Triple Negative Breast Cancer (TNBC)|Non-small Cell Lung Cancer (NSCLC)|Castration-resistant Prostate Cancer (CRPC)
Interventions: DRUG: Birabresib
Sponsor: Merck Sharp & Dohme LLC